ArticlePeerJ2026
Integrated transcriptomic and proteomic profiling in keloid tissue.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Keloid is a pathological skin fibrosis disease characterized by abnormal proliferation of dermal fibroblasts and excessive deposition of extracellular matrix (ECM). Its high recurrence rate necessitates an in-depth investigation of molecular mechanisms to develop effective treatment strategies. Methods: In this study, 20 samples of keloid tissue and adjacent normal skin were collected. Transcriptome sequencing and proteome analysis were performed, combined with differential expression analysis, functional enrichment, weighted gene co-expression network analysis (WGCNA), and protein interaction network analysis using the STRING platform, to systematically explore the molecular characteristics of keloid. Results: A total of 4,994 genes and 828 proteins were found to be differentially expressed in keloid tissue, with enrichment primarily observed in the PI3K-AKT, TGF-β, ECM-receptor interaction, and mitogen-activated protein kinase (MAPK) signaling pathways. Upregulated hub genes MAGED1, FN1, and COL5A2, as well as downregulated hub genes including IL20RA and CLDN4, were identified by WGCNA. Their respective interaction networks were associated with excessive ECM accumulation and disruption of epidermal structure. Conclusion: This study has confirmed that the regulatory network of epidermal dysfunction caused by excessive activation of fibroblasts in keloids through multi-omics integration, which provides a theoretical basis for multi-target therapy targeting ECM remodeling and PI3K-AKT/MAPK pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.